Analysis of hospitalized lung cancer patients with 35 of 48 taking HCQ, mortality OR 1.03,
p = 0.99.
Luo et al., 6/17/2020, retrospective, USA, North America, peer-reviewed, 31 authors.
risk of death, 2.2% higher, RR 1.02, p = 0.99, treatment 11 of 35 (31.4%), control 4 of 13 (30.8%), odds ratio converted to relative risk.